Chemical Structure : DBPR728
CAS No.:
2702965-64-6
DBPR728
(DBPR-728)
Catalog No.: PC-22141Not For Human Use, Lab Use Only.
DBPR728 is an oral bioavailable acyl-based prodrug of 6K465, which is a potent selective Aurora A (AURKA) inhibitor, effectively inhibits cancer cells overexpressing c-MYC- and/or N-MYC.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
DBPR728 is an oral bioavailable acyl-based prodrug of 6K465, which is a potent selective Aurora A (AURKA) inhibitor, effectively inhibits cancer cells overexpressing c-MYC- and/or N-MYC.
DBPR728 induced durable tumor regression of c-MYC- and/or N-MYC- overexpressing xenografts including SCLC, triple-negative breast cancer (TNBC), hepatocellular carcinoma and medulloblastoma.
DBPR728 at 300 mg/kg induced c-MYC reduction and cell apoptosis in the tumor xenografts for more than 7 days.
DBPR728 also synergized with the mTOR inhibitor everolimus to suppress c-MYC- or N-MYC- driven SCLC.
Physicochemical Properties
|
M.Wt
|
598.12
|
|
Formula
|
C29H37ClFN9O2
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
1-(5-((2-((1-(3-chloro-2-fluorobenzoyl)piperidin-4-yl)amino)-6-(4-ethylpiperazin-1-yl)pyrimidin-4-yl)amino)-3-methyl-1H-pyrazol-1-yl)propan-1-one
|
References
1. Chang CP, et al. Mol Cancer Ther. 2024 Apr 9. doi: 10.1158/1535-7163.MCT-23-0602.
Contact Us
sales@probechem.com
